Director of the Breast Medical Oncology Clinic & Program at the Jules Bordet Institut (IJB), H.U.B. and Professor of Medical Oncology at the Université Libre de Bruxelles, Belgium. Since 2016, he has been a member of the Executive and Research Boards of IJB. Since 2021, he is the chair of the Breast Cancer Group of the EORTC.

Prof. Michail Ignatiadis has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Seattle Genetics, Daiichi Sankyo, AstraZeneca, Menarini Stemline, Gilead Sciences, Rejuveron Senescence Therapeutics, Novartis, Roche, Pfizer, Natera Inc, and Inivata Inc. Travel grants from Gilead, Roche and AstraZeneca.